亚胺培南与头孢哌酮/舒巴坦联合应用对多重耐药鲍曼不动杆菌体外抗菌活性观察

摘要

Objective:To learn about the extracorporeal antibacterial activity of imipenem combined with cefoperazone/sulbactam on Multi- drug resistant Acinetobacter baumannii (MDR- AB) , and to provide reliable evidence for rational clinical application of antibiotics. Methods: 40 MDR- AB specimens in our hospital were collected. The MIC of the single application and the combined application of imipenem and cefoperazone/sulbactam on MDR- AB were detected with two methods, broth dilution technique and microdilution checkboard technique. Then the Fractional Inhibitory Concentration (FIC) were calculated and the extracorporeal antibacterial activity of their combination were validated. Results: The combined application of imipenem and cefoperazone/sulbactam lead to 12.5% synergistic effect, 55% partially synegistic effect, 20% additive effect, 12.5% indifferent effect and no antagonism on MDR- AB. Conclusion: Combined application got high antibacterial activity on MDR- AB, the synergistic and partially synergistic effect played the main role, and it was one of the best therapies for MDR- AB infection.%目的：了解亚胺培南与头孢哌酮/舒巴坦联合应用对多重耐药鲍曼不动杆菌的体外抗菌活性，为临床合理使用抗生素提供依据。方法：收集我院多重耐药鲍曼不动杆菌40株，用微量肉汤稀释法及联合药敏棋盘法检测亚胺培南与头孢哌酮/舒巴坦单用及联用的MIC值，计算部分抑菌指数（∑FIC），确定二者联用的体外抗菌效应。结果：亚胺培南与头孢哌酮/舒巴坦联合应用多重耐药菌株鲍曼不动杆菌协同作用12.5%，部分协同作用55.0%，相加作用20.0%，无关作用12.5%，拮抗作用0。结论：联合用药对多重鲍曼不动杆菌有较高的抗菌活性，主要表现为协同和部分协同作用联合用药，是临床治疗多重耐药鲍曼不动杆菌的最佳治疗方法之一。